ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1789

Time to Renal Insufficiency Based on 25(OH)-Vitamin D Levels

Michelle Petri1, Jessica Li2 and Daniel Goldman1, 1Johns Hopkins University School of Medicine, Timonium, MD, 2Johns Hopkins University, Baltimore, MD

Meeting: ACR Convergence 2020

Keywords: Disease Activity, Lupus nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Vitamin D is correctly classified as a sterol-hormone rather than a vitamin (Semin Nephrol 1986;6:4-20). It has multiple immunomodulatory effects, as well as cardiovascular and hematologic benefits (such as reduction in thrombosis). In SLE patients who are vitamin D insufficient/deficient, vitamin D supplementation clearly improves proteinuria (Arthritis Rheum 65:1865-71, 2013) with a plateau at a 25(OH)-vitamin D level of 40 ng/mL. In fact, vitamin D helps proteinuria in diverse renal diseases (Int J Environ Res Public Health 2018;15:1773).

Methods: The SLE patients met revised ACR or SLICC classification criteria. This analysis included 73,221 person months (6,102 person years) from 1,220 patients (93% female, 38% African-American, 52% Caucasian). 48.5% were diagnosed at age < 30 years. Vitamin D levels were measured regularly starting mid-2009. Renal insufficiency was defined as creatinine (CR) ≥1.5 mg/dl or < 50% function. For this analysis, a dataset with one record for each month of follow up for each person was constructed. Mean prior vitamin D levels were calculated over all previous months. Patients were followed from the first measure of 25(OH)-vitamin D level to first incident of renal insufficiency or their last recorded visit. To calculate the rate of renal insufficiency in each demographic or clinical subgroup, the number of renal insufficiency events was divided by the number of person months at risk and then converted to rates per 1,000 person years. Pooled logistic regression was used to assess the relationship between vitamin D blood levels and rates of renal insufficiency.

Results: Table 1 shows the association between patient characteristics and the rate of renal insufficiency. Renal insufficiency was more common in males, African-Americans and obese patients. Table 2 shows the association between Vitamin D level tertiles and the rate of renal insufficiency. There was a significantly elevated risk of renal insufficiency among those in the extremely low levels of 25(OH)-vitamin D (< 20 ng/mL). Figure 1 shows the trend of rates of renal insufficiency by vitamin D levels. The effect of 25(OH)-vitamin D < 20 ng/mL was clearly shown regardless if we used first, most recent or mean level of 25(OH)-vitamin D. Results were adjusted for race, age, sex and BMI.

Conclusion: The benefit of vitamin D supplementation to reduce proteinuria in SLE brought the benefit of this sterol-hormone as an immunomodulatory to the forefront. Now our data show that very low 25(OH)-vitamin D levels < 20 ng/mL are associated with renal insufficiency (adjusted for ethnicity, as African-Americans have lower levels).

Table 1: Rates of renal insufficiency events by demographics and patients characteristics

Table 2: Rates of renal insufficiency events by 25(OH)-vitamin D levels

Figure 1: Rates of renal insufficiency by 25(OH)-vitamin D levels


Disclosure: M. Petri, Astrazeneca, 2, 5, Exagen, 2, 5, GlaxoSmithKline (GSK), 2, 5, Eli Lilly and Company, 2, 5, AbbVie Inc., 5, Aleon Pharma International, Inc, 5, Amgen, 5, Annenberg Center for Health Sciences,, 5, Blackrock Pharma, 5, Bristol Myers Squibb, 5, Decision Resources, 5, Glenmark Pharmaceuticals, 5, INOVA, 5, IQVIA, 5, Janssen Pharmaceutical, 5, Merck EMD Serono, 5, Novartis, 5, Sanofi Japan, 5, Thermofisher, 5, UCB, 5; J. Li, None; D. Goldman, None.

To cite this abstract in AMA style:

Petri M, Li J, Goldman D. Time to Renal Insufficiency Based on 25(OH)-Vitamin D Levels [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/time-to-renal-insufficiency-based-on-25oh-vitamin-d-levels/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/time-to-renal-insufficiency-based-on-25oh-vitamin-d-levels/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology